LipUm
Umeå
About LipUm
Lipum aims to eliminate or alleviate painful symptoms for millions of patients suffering from chronic inflammatory diseases. Lipum has a biological anti-inflammatory drug candidate developed against Rheumatoid Arthritis (RA) – an autoimmune disease characterized by chronic inflammation of the joints. It often causes disability and lowers the quality of life for millions. Lipum also addresses the treatment of Juvenile Idiopathic Arthritis (JIA) that is a rare disease affecting children. A novel biological drug for this disease may be considered for an orphan drug designation. Treatment of other chronic inflammatory conditions is also explored. Related diseases are such as Crohn’s disease, ulcerative colitis, ankylosing spondylitis, and psoriatic arthritis. Lipum's biological anti-inflammatory drug candidate provides a novel mechanism of action. Therefore, it is assumed to have less adverse effects than current treatments in use.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $20.6M
- Funding stage: IPO
- Last round: Grant (Mar 2026)
- Ticker: sto:LIPUM
- Website: lipum.se
- Phone: +46 90 340 34 30
Industries & Categories
Biotechnology, Health Care, Pharmaceutical, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/lipum-153647 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.